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Scheme 1. Reagents and conditions: a) i) MsCl, Et3N, DCM, rt, 3h, ii) NaN3, DMF, 60 °C, 16h, 94% (2 steps); b) DIBAlH, 
DCM, -78 °C, 4h, 98%; c) aq. CH2O, K2CO3, MeOH, 50 °C, 24h, 84%; d) NaBH4, MeOH, 0 °C, 16h, 93%; e) i) TsCl, pyridine, 
rt, 3h, ii) 60 °C, 16h, 72%; f) K phthalimide, NaI, DMF, 90 °C, 16h, 86%; g) N2H4.H2O, EtOH, reflux, 4 h, 93%; h) BzCl, Et3N, 
DCM, 0 °C, 3h, 99%; i) i) PMe3, THF, H2O, ii) RCO2H, EDC.HCl, DIPEA, HOBt, DMF, rt, 16h; j) 35% TFA in H2O. 
SYNTHETIC ORGANIC CHEMISTRY 
BIOLOGICAL EVALUATION & X-RAY STRUCTURE 
In this poster we present a practical synthetic route that allows preparing a library of HAM derivatives with two non-identical aromatic moieties. A selection is given in Scheme 1 and 2.  
Scheme 2. Reagents and conditions: a) 2-chlorobenzoic acid, EDC.HCl, DIPEA, HOBt, DMF, rt, 16h, 69%; 
b) i) PMe3, THF, H2O, ii) RCO2H, EDC.HCl, DIPEA, HOBt, DMF, rt, 16h; c) 35% TFA in H2O. 
Compound EC50 (µM) 
  Pretreatment Co-treatment 
1 (HAM) 145.5 165.1 
2 96.97 93.55 
12 0.3890 7.976 
13 18.01 21.39 
14 13.67 52.62 
15 70.42 104.4 
18 0.2600 1.268 
19 3.376 98.93 



























• We developed a practical synthetic route that allows preparing a library of HAM analogues. 
 
• Several compounds show promising activity on biofilm susceptibility (Table 1). 5-ortho-
chlorobenzamide 12 emerges as one of the strongest potentiators (EC50 = 0.389 µM). 
 
• The potentiators were not cytotoxic up to a concentration of 128µM (highest concentration 
tested) in MRC-5 lung fibroblast cells, suggesting acceptable therapeutic windows (not shown). 
 
• Ortho-substitution of the benzamide increases activity. Twisting the benzamide group out of 
the plane (Figure 2) tends to improve interaction with the target. 
• HAM analogues potentiate the activity of several classes of antibiotics (not shown). 
 
• The most potent analogues (including 12) significantly enhance survival of infected 
Caenorhabditis elegans (Figure 3). 
 
• In a mouse mastitis model, significantly less CFU are present after treatment with the 
combination of cefalexin (CEF) and 12, compared to treatment with antibiotic alone (Figure 4). 
 
• In all cases, MIC values were higher than 500 µM, the highest concentration tested (not 
shown).  
Figure 1: Identification of hamamelitannin analogue 12, with exceptional antibiofilm activity in Staphylococcus aureus. 
Table 1: selection of HAM analogues with in vitro results. Figure 2: asymmetric unit of the crystal structure of 12. Figure 4: Log(CFU)/g mammary gland (average ± sd) of mice infected with S. aureus, reveiving  
no treatment, treatment with potentiator, or treatment with cefalexin (CEF) and potentiator.  


































 HAM (1) 
EC50 = 73.80 µM 
12 
EC50 = 1.854 µM  
Figure 3: C. elegans survival after 48h for uninfected (NI) and infected (I) nematodes receiving no treatment (NT), treatment  
with HAM, or treatment with 12. EC50 values are expressed as the concentration needed to increase survival by 50%. 
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